Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of LMTM in Alzheimer's disease or behavioral variant frontotemporal dementia
NL-OMON41951Phase 3Recruiting
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydromethylthionine mesylate in Alzheimer's disease (AD) and frontotemporal dementia (FTD), sponsored by TauRx Therapeutics Ltd. Primary endpoints: Long-term safety and tolerability of LMTM and Continued access to therapy. Started Jun 2016; status: recruiting.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON41951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41951.